Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies and technology platforms for the pharmaceutical industry. Founded in 1987 in San Diego, US, Ligand Pharmaceuticals specializes in the clinical development of biopharmaceuticals. The company has undergone various strategic pivots to enhance its operational focus and has no known parent or subsidiary relationships.

Ligand was formed by Taurus Biosciences and has been led by CEO John Higgins, with key executives Prathik Johnson and Todd Davis. The company has raised a total of USD 2. 00 mn, with its most recent deal occurring in January 2014, backed by the Merck Global Health Innovation Fund. Ligand Pharmaceuticals manages a vast portfolio of over 90 partnered commercial and development-stage programs.

Its primary technology platforms, Captisol® and NITRICIL™, are essential in drug development applications, addressing health issues across various disease areas such as cancer and diabetes. Ligand's global reach extends to over 70 countries, facilitating collaborations with major pharmaceutical manufacturers and biopharmaceutical partners. In the most recent fiscal year of 2024, Ligand Pharmaceuticals reported a revenue of USD 139. 66 mn, accompanied by an EBITDA of USD 12.

63 mn. The company generates income through licensing agreements and royalties from sales of their partnered products, leveraging a royalty structure ranging from high-single digits to 13% depending on specific agreements. Ligand Pharmaceuticals is committed to expanding its product offerings and targeting new markets. With the recent funding of USD 2.

00 mn, the company plans to invest in the development of upcoming products, though specific timelines for launches have not been disclosed. Additionally, Ligand aims to extend its reach into emerging markets by the end of 2024, enhancing its global footprint. Following the exit of all VC investors in 2014, the company's strategic initiatives are more focused on direct partnerships and leveraging existing technologies.